AU2016319133B2 - Enhanced delivery of drugs to the brain - Google Patents

Enhanced delivery of drugs to the brain Download PDF

Info

Publication number
AU2016319133B2
AU2016319133B2 AU2016319133A AU2016319133A AU2016319133B2 AU 2016319133 B2 AU2016319133 B2 AU 2016319133B2 AU 2016319133 A AU2016319133 A AU 2016319133A AU 2016319133 A AU2016319133 A AU 2016319133A AU 2016319133 B2 AU2016319133 B2 AU 2016319133B2
Authority
AU
Australia
Prior art keywords
antibody
ser
light chain
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016319133A
Other languages
English (en)
Other versions
AU2016319133A1 (en
Inventor
Mark C. Glassy
Rishab K. Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nascent Biotech Inc
Original Assignee
Nascent Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nascent Biotech Inc filed Critical Nascent Biotech Inc
Publication of AU2016319133A1 publication Critical patent/AU2016319133A1/en
Application granted granted Critical
Publication of AU2016319133B2 publication Critical patent/AU2016319133B2/en
Priority to AU2023226718A priority Critical patent/AU2023226718A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2016319133A 2015-09-11 2016-09-09 Enhanced delivery of drugs to the brain Ceased AU2016319133B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023226718A AU2023226718A1 (en) 2015-09-11 2023-09-07 Enhanced delivery of drugs to the brain

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562217608P 2015-09-11 2015-09-11
US62/217,608 2015-09-11
US201562247490P 2015-10-28 2015-10-28
US62/247,490 2015-10-28
PCT/US2016/051128 WO2017044866A2 (en) 2015-09-11 2016-09-09 Enhanced delivery of drugs to the brain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023226718A Division AU2023226718A1 (en) 2015-09-11 2023-09-07 Enhanced delivery of drugs to the brain

Publications (2)

Publication Number Publication Date
AU2016319133A1 AU2016319133A1 (en) 2018-04-05
AU2016319133B2 true AU2016319133B2 (en) 2023-06-08

Family

ID=58236547

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016319133A Ceased AU2016319133B2 (en) 2015-09-11 2016-09-09 Enhanced delivery of drugs to the brain
AU2023226718A Abandoned AU2023226718A1 (en) 2015-09-11 2023-09-07 Enhanced delivery of drugs to the brain

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023226718A Abandoned AU2023226718A1 (en) 2015-09-11 2023-09-07 Enhanced delivery of drugs to the brain

Country Status (7)

Country Link
US (2) US11028155B2 (enExample)
EP (2) EP3347380B1 (enExample)
JP (4) JP2018531625A (enExample)
AU (2) AU2016319133B2 (enExample)
CA (1) CA2998132A1 (enExample)
IL (1) IL257983A (enExample)
WO (1) WO2017044866A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018531625A (ja) 2015-09-11 2018-11-01 ナセント バイオテック インコーポレイテッド 脳への向上した薬物送達の方法
US11492394B1 (en) 2021-10-29 2022-11-08 Nascent Biotech, Inc. Kits and containers for treating vimentin expressing tumors
WO2023075790A1 (en) * 2021-10-29 2023-05-04 Nascent Biotech, Inc. Kits and containers for treating vimentin expressing tumors
CN114181972A (zh) * 2021-11-23 2022-03-15 上海本导基因技术有限公司 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055404A1 (en) * 2011-10-10 2013-04-18 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
US20130287802A1 (en) * 2012-04-30 2013-10-31 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
WO2014072741A1 (en) * 2012-11-09 2014-05-15 Fusion Antibodies Limited Humanised antibody and method of production thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3223885A1 (de) 1982-06-26 1983-12-29 Basf Ag, 6700 Ludwigshafen Makroporoese, hydrophile traeger fuer enzyme
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US20020099179A1 (en) 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
JP2610792B2 (ja) 1993-02-26 1997-05-14 株式会社ディ・ディ・エス研究所 多糖誘導体および薬物担体
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
MX9504664A (es) 1994-03-07 1997-05-31 Dow Chemical Co Conjugados de dendrimeros bioactivos y/o dirigidos.
WO1995025764A1 (en) 1994-03-23 1995-09-28 Meiji Seika Kabushiki Kaisha Double-stranded derivative of polyoxyethylene-containing lipid
JP3699141B2 (ja) 1994-09-24 2005-09-28 伸彦 由井 超分子構造の生体内分解性医薬高分子集合体及びその調製方法
US5490840A (en) 1994-09-26 1996-02-13 General Electric Company Targeted thermal release of drug-polymer conjugates
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US20040126829A1 (en) 2001-12-18 2004-07-01 Hildebrand William H. Anti-HLA assay and methods
JP2007512846A (ja) * 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
CA2602316A1 (en) 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
WO2008028686A2 (en) * 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
US20150218280A1 (en) * 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
JP2018531625A (ja) 2015-09-11 2018-11-01 ナセント バイオテック インコーポレイテッド 脳への向上した薬物送達の方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013055404A1 (en) * 2011-10-10 2013-04-18 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
US20130287802A1 (en) * 2012-04-30 2013-10-31 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
WO2014072741A1 (en) * 2012-11-09 2014-05-15 Fusion Antibodies Limited Humanised antibody and method of production thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Satelli, A and Li, D., Cell Mol Life Sci, (2011), vol. 68, no. 18, pages 3033-3046, doi:10.1007/s00018-011-0735-1 *
Vincke, C. et al., 'General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold', J Biol Chem, (2009), vol. 284, no. 5, pages 3273-3284, doi: 10.1074/jbc.M806889200. *

Also Published As

Publication number Publication date
EP4548979A2 (en) 2025-05-07
JP7361980B2 (ja) 2023-10-16
JP2024001124A (ja) 2024-01-09
EP3347380A2 (en) 2018-07-18
EP3347380B1 (en) 2024-09-25
JP2018531625A (ja) 2018-11-01
JP2021191269A (ja) 2021-12-16
JP2023126840A (ja) 2023-09-12
AU2023226718A1 (en) 2023-09-28
US20170073400A1 (en) 2017-03-16
US11028155B2 (en) 2021-06-08
US20210269513A1 (en) 2021-09-02
WO2017044866A2 (en) 2017-03-16
EP4548979A3 (en) 2025-07-23
CA2998132A1 (en) 2017-03-16
HK1256875A1 (en) 2019-10-04
IL257983A (en) 2018-05-31
WO2017044866A3 (en) 2017-06-08
AU2016319133A1 (en) 2018-04-05
EP3347380A4 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
JP7393337B2 (ja) 抗ｂ７－ｈ４抗体、その抗原結合断片及びその医薬用途
JP2024050548A (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
US10590196B2 (en) Antibodies targeting G-protein coupled receptor and methods of use
JP7361980B2 (ja) 脳への向上した薬物送達の方法
JP7663883B2 (ja) Ｃｌｄｎ１８．２抗体及びその使用
WO2018161872A1 (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
JP7522482B2 (ja) クローディン１８．２の抗体及びその使用
TW202202525A (zh) 抗b7h4抗體及其雙抗和應用
WO2023138579A1 (zh) 抗b7-h7抗体或其抗原结合片段及制备方法和应用
WO2019080889A1 (zh) 抗csf-1r抗体、其抗原结合片段及其医药用途
JP2022529340A (ja) ヒトｃｄ４７を標的とする抗体
CN103588882B (zh) 针对人cd22抗体的抗独特型抗体及其应用
CN119698294A (zh) 结合γ-δT细胞受体的变体抗体
HK1256875B (en) Enhanced delivery of drugs to the brain
AU2024305430A1 (en) Antibody binding to human ccr8 and the use thereof
HK40070445A (en) Anti-b7h4 antibody, and bispecific antibody and use thereof
Putelli Human antibody phage technology-isolation and characterization of monoclonal antibodies for the targeting of cancer and rheumatoid arthritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired